The Hemostasis and Thrombosis Laboratory is dedicated to the diagnosis and treatment of bleeding disorders and thrombosis, serving both inpatients and outpatients. The Unit provides advanced diagnostic services to identify coagulation defects, with a particular focus on well-known conditions such as hemophilia and factor VII deficiency. Patients with hemophilia are managed through a structured clinical and research follow-up program, which includes comprehensive laboratory monitoring of therapeutic outcomes.
In the area of bleeding disorders, the Unit also specializes in diagnosing and treating platelet function defects and hereditary macrothrombocytopenia syndromes. Additionally, the Unit plays a key role in the research and clinical management of venous and arterial thrombosis, providing diagnostic and therapeutic care for hospitalized patients. It is also responsible for the differential diagnosis of microangiopathies—a group of rare, potentially life-threatening conditions. This includes laboratory diagnosis and ongoing monitoring of patients with immune thrombotic thrombocytopenia.
The Unit is internationally recognized for its expertise in maternal-fetal medicine. In this field, we support women at risk for gestational vascular complications, including recurrent miscarriage, fetal death, gestational hypertension, fetal growth restriction, pregnancy-related venous thromboembolism, obstetric hemorrhage, and postpartum hemorrhage. Given the strong correlation between maternal mortality and thrombotic or hemorrhagic complications, our mission is to reduce maternal mortality by minimizing these risks.
We also provide a broad range of laboratory tests, including thrombophilia screening (e.g., antiphospholipid antibodies, factor V Leiden, and prothrombin variant), to identify individuals at risk for primary or recurrent thrombotic events. Additionally, routine investigations focus on somatic mutations—JAK2, MPL, and calreticulin—which are associated with venous thrombosis in unusual sites (such as splanchnic or cerebral veins) and myeloproliferative neoplasms.
